Bristol-Myers Squibb Company (NYSE:BMY) is scheduled to announce Q2 earnings results on July 31st, before markets open.

This was the stock's fifth consecutive day of losses.

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Novo Nordisk promoted Maziar Mike Doustdar to president and CEO, effective August 7. The Food and Drug Administration tapped newly appointed George Tidmarsh as acting Center for Biologics Evaluation ...

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...